However, based on the beneficial effects at longer follow-up [91], a treatment duration of at least 12 months after an ACS, and long-term treatment in CCS should be considered, in particular in patients with elevated markers of inflammation (such as hs-CRP), in patients with recurrent adverse cardiovascular events despite guideline-directed medical therapy, and in patients with other high risk features, such as multivessel coronary artery disease or ASCVD involving more than one vascular territory (e.g., CAD associated with peripheral artery disease or carotid artery stenosis). The gene discussed is CRP; the disease is coronary artery disorder.